Inmune Bio, Inc. Forecast, price target & analysts
Inmune Bio, Inc. Target price 2025 - Analyst rating & recommendation
Inmune Bio, Inc. Classifications & Recommendation:
Inmune Bio, Inc. Price Target
| Target Price | $23.33 |
| Price | $7.85 |
| Potential |
197.24%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Inmune Bio, Inc. 2026 .
The average Inmune Bio, Inc. target price is $23.33.
This is
197.24%
register free of charge
$30.00
282.17%
register free of charge
$20.00
154.78%
register free of charge
|
|
| A rating was issued by 6 analysts: 6 Analysts recommend Inmune Bio, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Inmune Bio, Inc. stock has an average upside potential 2026 of
197.24%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.16 | 0.01 |
| 56.76% | 95.63% | |
| Net Margin | -23,139.94% | -719,733.21% |
| 154.07% | 3,010.35% |
6 Analysts have issued a sales forecast Inmune Bio, Inc. 2024 . The average Inmune Bio, Inc. sales estimate is
This results in the following potential growth metrics:
4 Inmune Bio, Inc. Analysts have issued a net profit forecast 2024. The average Inmune Bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.67 | -2.27 |
| 9.87% | 35.93% | |
| P/E | negative | |
| EV/Sales | 20,487.14 |
4 Analysts have issued a Inmune Bio, Inc. forecast for earnings per share. The average Inmune Bio, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Inmune Bio, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Inmune Bio, Inc....
Current Inmune Bio, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Maxim Group | Locked ➜ Locked | Locked | Feb 13 2025 |
| Scotiabank | Locked ➜ Locked | Locked | Feb 11 2025 |
| Alliance Global Partners | Locked ➜ Locked | Locked | Oct 21 2024 |
| Raymond James | Locked ➜ Locked | Locked | Sep 27 2024 |
| Scotiabank | Locked ➜ Locked | Locked | Aug 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Maxim Group: Locked ➜ Locked
|
Feb 13 2025 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Feb 11 2025 |
|
Locked
Alliance Global Partners: Locked ➜ Locked
|
Oct 21 2024 |
|
Locked
Raymond James: Locked ➜ Locked
|
Sep 27 2024 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Aug 22 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
